申请人:Pfizer Limited
公开号:EP0274234A2
公开(公告)日:1988-07-13
Compounds of the formula
wherein A completes a 4 or 7 membered carbocyclic ring which may be saturated or mono-unsaturated and which may optionally be fused to a further saturated or unsaturated 5 or 6 membered carbocyclic ring; B is (CH2)m wherein m is an integer of from 1 to 3; each of R and R4 is independently H, C1-C6 alkyl, benzyl or an alternative biolabile ester-forming group; R1 is H or C1-C4 alkyl; R2 and R3 are each independently H, OH, C1-C4 alkyl or C1-C4 alkoxy; and R5 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl(C2-C6 alkynyl), C3-C7 cycloalkyl, C3-C7 cycloalkenyl, C1-C6 alkoxy, -NR6R7, -NR8COR9, -NR8SO2R9 or a saturated heterocyclic group; or C1-C6 alkyl substituted by one or more substituents chosen from halo, hydroxy, C1-C6 alkoxy, C2-C6 hydroxyalkoxy, C1-C6 alkoxy(C1-C6 alkoxy), C3-C7 cycloalkyl, C3-C7 cycloalkenyl, aryl, aryloxy, arlyoxy(CI-C4 alkoxy), heterocyclyl, heterocyclyloxy, -NR6R7, -NR8COR9, -NR8SO2R9, -CONR6R7, -SH, -S(O)pR10, -COR11 or -CO2R12; wherein R6 and R7 are each independently H, C1-C4 alkyl, C3-C7 cycloalkyl (optionally substituted by hydroxy or C1-C4 alkoxy), aryl, aryl(C1-C4 alkyl), CrCs alkoxyalkyl, or heterocyclyl; or the two groups R6 and R7 are taken together with the nitrogen to which they are attached to form a pyrrolidinyl, piperidino, morpholino, piperazinyl or N-(C1-C4 alkyl)-piperazinyl group; R8 is H or C1-C4 alkyl; R9 is C1-C4 alkyl, CF3, aryl, aryl(CI-C4 alkyl), aryl(C1-C4 alkoxy), heterocycyl, C1-C4 alkoxy or NR6R7 wherein R6 and R7 are as previously defined; R10 is C1-C4 alkyl, aryl, heterocyclyl or NR6R7 wherein R6 and R7 are as previously defined; R11 is C1-C4 alkyl, C3-C7 cycloalkyl, aryl or heterocyclyl; R12 is H or Ci-C4 alkyl; and p is 0, 1 or 2; or a pharmaceutically acceptable salts thereof or bioprecursor therefor are diuretic agents having utility in the treatment of hypertension, heart failure, renal insufficiency and in other disorders.
式中的化合物
其中 A 是一个 4 或 7 个成员的碳环,可以是饱和的或单不饱和的,并可选择与另一个饱和或不饱和的 5 或 6 个成员的碳环融合;B 是 (
CH2)m,其中 m 是 1 至 3 的整数;R 和 R4 各自独立地是 H、C1-C6 烷基、苄基或另一种
生物可成酯基团;R1 是 H 或 C1-C4 烷基;R2 和 R3 各自独立地是 H、OH、C1-C4 烷基或 C1-C4 烷氧基;R5 是 C1-C6 烷基、C2-C6 烯基、C2-C6 炔基、芳基(C2-C6 炔基)、C3-C7 环烷基、C3-C7 环烯基、C1-C6 烷氧基、-NR6R7、-NR8COR9、-NR8SO2R9 或饱和杂环基团;或被一个或多个取代基取代的 C1-C6 烷基,取代基选自卤代、羟基、C1-C6 烷氧基、C2-C6 羟基烷氧基、C1-C6 烷氧基(C1-C6 烷氧基)、C3-C7 环烷基、C3-C7环烯基、芳基、芳氧基、烯氧基(CI-C4 烷氧基)、杂环基、杂环氧基、-NR6R7、-NR8COR9、-NR8SO2R9、-CONR6R7、-SH、-S(O)pR10、-COR11 或 -CO2R12;其中 R6 和 R7 各自独立地为 H、C1-C4 烷基、C3-C7 环烷基(任选被羟基或 C1-C4 烷氧基取代)、芳基、芳基(C1-C4 烷基)、CrCs 烷氧基烷基或杂环烷基;或两个基团 R6 和 R7 与它们所连接的氮一起形成
吡咯烷基、
哌啶基、吗啉基、
哌嗪基或 N-(C1-C4 烷基)-
哌嗪基;R8 为 H 或 C1-C4 烷基;R9 是 C1-C4 烷基、
CF3、芳基、芳基(CI-C4 烷基)、芳基(C1-C4 烷氧基)、杂环基、C1-C4 烷氧基或 NR6R7,其中 R6 和 R7 如前定义;R10 是 C1-C4 烷基、芳基、杂环基或 NR6R7,其中 R6 和 R7 如前定义;R11 是 C1-C4 烷基、C3-C7 环烷基、芳基或杂环基;R12 是 H 或 Ci-C4 烷基;以及 p 是 0、1 或 2;或其药学上可接受的盐或
生物前体。